Literature DB >> 27151736

NEDD8 and HDACs: promising cotargets in AML.

Kapil N Bhalla1, Warren Fiskus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27151736      PMCID： PMC4859193          DOI： 10.1182/blood-2016-02-699058

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  NEDD8 pathways in cancer, Sine Quibus Non.

Authors:  Ian R Watson; Meredith S Irwin; Michael Ohh
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

Review 2.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 3.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Authors:  Yongchao Zhao; Meredith A Morgan; Yi Sun
Journal:  Antioxid Redox Signal       Date:  2014-02-20       Impact factor: 8.401

4.  Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Authors:  Ronan T Swords; Kevin R Kelly; Peter G Smith; James J Garnsey; Devalingam Mahalingam; Ernest Medina; Kelli Oberheu; Swaminathan Padmanabhan; Michael O'Dwyer; Steffan T Nawrocki; Francis J Giles; Jennifer S Carew
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

5.  The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Authors:  Liang Zhou; Shuang Chen; Yu Zhang; Maciej Kmieciak; Yun Leng; Lihong Li; Hui Lin; Kathryn A Rizzo; Catherine I Dumur; Andrea Ferreira-Gonzalez; Mohamed Rahmani; Lawrence Povirk; Sri Chalasani; Allison J Berger; Yun Dai; Steven Grant
Journal:  Blood       Date:  2016-02-05       Impact factor: 22.113

6.  Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Authors:  Ronan T Swords; Harry P Erba; Daniel J DeAngelo; Dale L Bixby; Jessica K Altman; Michael Maris; Zhaowei Hua; Stephen J Blakemore; Hélène Faessel; Farhad Sedarati; Bruce J Dezube; Francis J Giles; Bruno C Medeiros
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998

7.  CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.

Authors:  Maria Paola Martelli; Valentina Pettirossi; Christian Thiede; Elisabetta Bonifacio; Federica Mezzasoma; Debora Cecchini; Roberta Pacini; Alessia Tabarrini; Raffaella Ciurnelli; Ilaria Gionfriddo; Nicla Manes; Roberta Rossi; Linda Giunchi; Uta Oelschlägel; Lorenzo Brunetti; Marica Gemei; Mario Delia; Giorgina Specchia; Arcangelo Liso; Mauro Di Ianni; Francesco Di Raimondo; Franca Falzetti; Luigi Del Vecchio; Massimo F Martelli; Brunangelo Falini
Journal:  Blood       Date:  2010-07-15       Impact factor: 22.113

8.  A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

Authors:  Mark H Kirschbaum; Kenneth A Foon; Paul Frankel; Christopher Ruel; Bernadette Pulone; Joseph M Tuscano; Edward M Newman
Journal:  Leuk Lymphoma       Date:  2014-02-24

Review 9.  Ubiquitylation, neddylation and the DNA damage response.

Authors:  Jessica S Brown; Stephen P Jackson
Journal:  Open Biol       Date:  2015-04       Impact factor: 6.411

10.  Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites.

Authors:  Jessica S Brown; Natalia Lukashchuk; Matylda Sczaniecka-Clift; Sébastien Britton; Carlos le Sage; Patrick Calsou; Petra Beli; Yaron Galanty; Stephen P Jackson
Journal:  Cell Rep       Date:  2015-04-23       Impact factor: 9.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.